Researchers have demonstrated that patients who at their initial scan tested negative for lung cancer but within 2 years developed the disease had poorer survival outcomes compared with patients who initially had a noncancerous positive scan.
Study suggests screening for the activity of two genes could identify individuals with an increased risk of dying from breast cancer.
Researchers have compiled a comprehensive list of 788 blood-based biomarkers studied over the past 5 years that could be used to develop early stage cancer screening tests.
In this article, the authors outline their expectations for growth in RNA-based cancer diagnostics, particularly in immune oncology, and argue that those same forces that brought DNA sequencing into clinical laboratories – falling sequencing costs and a rapidly growing list of actionable markers – will lead to emergence of clinical RNA sequencing, despite the challenges.
The authors review the histologic subtypes and highlight how recent advances in elucidating the molecular pathogenesis of these tumors have refined diagnosis and prognostication.